Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study - Archive ouverte HAL Access content directly
Journal Articles Annals of Hematology Year : 2016

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study

(1, 2, 3) , (4, 5, 2) , (2) , (2) , (5) , (5) , (3) , (3) , (3) , (6) , (7) , (4) , (2) , (1) , (1, 3) , (1, 5, 4, 2) , (2)
1
2
3
4
5
6
7
Aurélie Chauveau
Marc Zandecki
  • Function : Author
  • PersonId : 920770

Abstract

A high number of circulating CD34+ cells has been advocated to distinguish primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms. We reevaluated the diagnostic interest of measuring circulating CD34+ cells in 26 healthy volunteers and 256 consecutive patients at diagnosis for whom a myeloproliferative neoplasm was suspected. The ROC curve analysis showed that a number of CD34+ <10/μl excludes the diagnosis of primary myelofibrosis with a sensitivity of 97%and a specificity of 90%(area under the curve: 0.93 [0.89–0.98]; p < 0.001). Patients with PMF harboring a CALR mutation had more circulating CD34+ cells than patients with either a JAK 2 or MPL mutation (p = 0.02 and p < 0.01, respectively). These results suggest that this fast, simple, non-invasive, and standardized test is of particular interest to exclude the diagnosis of primary myelofibrosis.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01382431 , version 1 (17-10-2016)

Identifiers

Cite

Corentin Orvain, Damien Luque Paz, Irène Dobo, Laurane Cottin, Geneviève Le Calvez, et al.. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Annals of Hematology, 2016, 95 ((11)), pp.1819-23. ⟨10.1007/s00277-016-2784-x⟩. ⟨inserm-01382431⟩
65 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More